Thrilled to have worked w/ The Pike Lab, Chad Rusthoven, & colleagues in this Journal of Clinical Oncology publication! 👏 ▶️ascopubs.org/doi/full/10.12… Key points listed below! Optimal use of upfront SRS for brain mets in #EGFR & #ALK pts is controversial.

Check out the TURBO-NSCLC study looking at Up-Front next gen TKI alone or combination with SRS for brain mets. We found that combination with SRS had better local control and time to progression especially for lesions >1cm. ASTRO Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Any benefit w/ upfront SRS for EGFR and ALK positive NSCLC brain Mets treated w/CNS penetrant TKI? · ↑↑LC and CNS control · No diff OS · 10% symptomatic RN after SRS ascopubs.org/doi/10.1200/JC…

What is the role for SRS to brain metastases up front for #EGFR or #ALK NSCLC? Retrospective TURBO-NSCLC study Journal of Clinical Oncology shows early radiation improves CNS control but not survival when CNS-penetrant TKIs are used. Greater benefit with larger tumors. ascopubs.org/doi/10.1200/JC…

Journal of Clinical Oncology: TURBO-NSCLC (ascopubs.org/doi/10.1200/JC…) was a multi-institutional cohort study of 317 treatment-naive EGFR or ALK NSCLC pts with Brain Mets who received TKI w/wo up-front SRS. SRS was associated with superior CNS control. Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center

A new multi-institution study from The Pike Lab and colleagues in Journal of Clinical Oncology finds adding up-front stereotactic radiosurgery improved time to CNS progression in patients with brain metastases from EGFR- and ALK-driven non-small cell lung cancer. #NSCLC bit.ly/3WDgwcF

🧠⚡️🫁☢️New in Journal of Clinical Oncology from The Pike Lab Chad Rusthoven: The addition of up-front #radiation #SRS to CNS-penetrant #TKI ⬆️time-to-CNS progression & local control (but not OS) in pts with brain mets from #EGFR #ALK-driven #NSCLC #lungcancer. #lcsm #radonc ascopubs.org/doi/10.1200/JC…

Any role of up-front SRS in lung pts with brain Mets and EGFR or ALK targetable mutations who is receiving the 3th generation TKIs? JCO July 24, 2024 SRS improves time to CNS progression, particularly for lesion > 1 cm OS is similar MDT and personalized approach are crucial.

In view of TURBO-NSCLC study results, would you offer TKIs + SRS in EGFR/ALK+ve NSCLC patients? OncoAlert OncoViews Oncology Brothers ascopubs.org/doi/abs/10.120… #NSCLC #LungCancer #Oncology #TKI #SRS #EGFR #ALK #CancerResearch #TURBONSCStudy

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for #BrainMetastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-#NSCLC): brnw.ch/21wLHQU Tony Wang #lcsm #btsm